Biology of Graft-versus-Host Responses: Recent Insights

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 1 SUPPL., 2013, Pages

  MacDonald, Kelli P ^a   Shlomchik, Warren D ^b   Reddy, Pavan ^c  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b YALE CANCER CENTER   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BZ 423; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MICRORNA 155; NOTCH RECEPTOR; PROTEASOME; PROTEIN KINASE C; RAPAMYCIN; STAT PROTEIN; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; DENDRITIC CELL; DONOR; EPIGENETICS; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTONE ACETYLATION; HUMAN; NONHUMAN; PLASMACYTOID DENDRITIC CELL; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIGEN-PRESENTING CELLS; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84871895053     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.11.005     Document Type: Article

References (51)

1. Matte C.C., Liu J., Cormier J., et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med 2004, 10:987-992.
2. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999, 285:412-415.
3. Teshima T., Ordemann R., Reddy P., et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002, 8:575-581.
4. Koyama M., Kuns R.D., Olver S.D., et al. Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. Nat Med 2012, 18:135-142.
5. Toubai T., Tawara I., Sun Y., et al. Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells. Blood 2012, 119:3844-3853.
6. Stenger E.O., Turnquist H.R., Mapara M.Y., Thomson A.W. Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity. Blood 2012, 119:5088-5103.
7. Wilson J., Cullup H., Lourie R., et al. Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. J Exp Med 2009, 206:387-398.
8. Zhang Y., Louboutin J.P., Zhu J., Rivera A.J., Emerson S.G. Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. J Clin Invest 2002, 109:1335-1344.
9. Li H., Demetris A.J., McNiff J., et al. Profound depletion of host conventional dendritic cells, plasmacytoid dendritic cells, and B cells does not prevent graft-versus-host disease induction. J Immunol 2012, 188:3804-3811.
10. Koyama M., Hashimoto D., Aoyama K., et al. Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells. Blood 2009, 113:2088-2095.
11. Banovic T., Markey K.A., Kuns R.D., et al. Graft-versus-host disease prevents the maturation of plasmacytoid dendritic cells. J Immunol 2009, 182:912-920.
12. Markey K.A., MacDonald K.P., Hill G.R. Recipient plasmacytoid DCs are not required to prime allogeneic T-cell responses after BMT. Blood 2009, 113:6038-6039.
13. Hashimoto D., Chow A., Greter M., et al. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J Exp Med 2011, 208:1069-1082.
14. MacDonald K.P., Palmer J.S., Cronau S., et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood 2010, 116:3955-3963.
15. Matte-Martone C., Wang X., Anderson B., et al. Recipient B cells are not required for graft-versus-host disease induction. Biol Blood Marrow Transplant 2010, 16:1222-1230.
16. Rowe V., Banovic T., MacDonald K.P., et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood 2006, 108:2485-2492.
17. Beschorner W.E., Farmer E.R., Saral R., Stirling W.L., Santos G.W. Epithelial class II antigen expression in cutaneous graft-versus-host disease. Transplantation 1987, 44:237-243.
18. Lampert I.A., Suitters A.J., Chisholm P.M. Expression of Ia antigen on epidermal keratinocytes in graft-versus-host disease. Nature 1981, 293:149-150.
19. Bland P.W., Whiting C.V. Induction of MHC class II gene products in rat intestinal epithelium during graft-versus-host disease and effects on the immune function of the epithelium. Immunology 1992, 75:366-371.
20. Mason D.W., Dallman M., Barclay A.N. Graft-versus-host disease induces expression of Ia antigen in rat epidermal cells and gut epithelium. Nature 1981, 293:150-151.
21. Markey K.A., Banovic T., Kuns R.D., et al. Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplantation. Blood 2009, 113:5644-5649.
22. Markey K.A., Koyama M., Kuns R.D., et al. Immune insufficiency during GVHD is due to defective antigen presentation within dendritic cell subsets. Blood 2012, 119:5918-5930.
23. Wang X., Li H., Matte-Martone C., et al. Mechanisms of antigen presentation to T cells in murine graft-versus-host disease: Cross-presentation and the appearance of cross-presentation. Blood 2011, 118:6426-6437.
24. Hill G.R., Olver S.D., Kuns R.D., et al. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood 2010, 116:819-828.
25. Srinivasan M., Flynn R., Price A., et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood 2012, 119:1570-1580.
26. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006, 108:756-762.
27. Ratanatharathorn V., Ayash L., Reynolds C., et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003, 9:505-511.
28. Lu Y., Giver C.R., Sharma A., et al. IFN-gamma and indoleamine-2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity. Blood 2012, 119:1075-1085.
29. Li N., Matte-Martone C., Zheng H., et al. Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood 2011, 118:5965-5976.
30. Matte C.C., Cormier J., Anderson B.E., et al. Graft-versus-leukemia in a retrovirally induced murine CML model: Mechanisms of T-cell killing. Blood 2004, 103:4353-4361.
31. Matte-Martone C., Liu J., Jain D., McNiff J., Shlomchik W.D. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL. Blood 2008, 111:3884-3892.
32. Zheng H., Matte-Martone C., Li H., et al. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Blood 2008, 111:2476-2484.
33. Matte-Martone C., Venkatesan S., Tan H.S., et al. Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): Shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant. J Immunol 2011, 187:1653-1663.
34. Choi S., Reddy P. HDAC inhibition and graft versus host disease. Mol Med 2011, 17:404-416.
35. Reddy P., Sun Y., Toubai T., et al. Histone deacetylase inhibition modulates indoleamine-2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 2008, 118:2562-2573.
36. He S., Wang J., Kato K., et al. Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. Blood 2012, 119:1274-1282.
37. Choi J., Ritchey J., Prior J.L., et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 2010, 116:129-139.
38. Zhang Y., Sandy A.R., Wang J., et al. Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease. Blood 2011, 117:299-308.
39. Toubai T., Sun Y., Tawara I., et al. Ikaros-Notch axis in host hematopoietic cells regulates experimental graft-versus-host disease. Blood 2011 Jul 7, 118(1):192-204.
40. Powell J.D., Pollizzi K.N., Heikamp E.B., Horton M.R. Regulation of immune responses by mTOR. Annu Rev Immunol 2012, 30:39-68.
41. Gatza E., Wahl D., Opipari A., et al. Manipulating the bioenergetics of alloreactive T calls causes their selective apoptosis and arrests graft-versus-host disease. Sci Translat Med 2011, 3.
42. Sun K., Welniak L.A., Panoskaltsis-Mortari A., et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004, 101:8120-8125.
43. Sun K., Welniak L.A., Wilkins D., et al. PS-341 administration inhibits acute graft-versus-host disease and preserves graft-versus-tumor after allogeneic BMT in advanced tumor-bearing mice. Blood 2003, 102(11 suppl):192a.
44. Koreth J., Stevenson K.E., Kim H.T., et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 2009, 114:3956-3959.
45. Zanin-Zhorov A., Dustin M.L., Blazar B.R. PKC-theta function at the immunological synapse: Prospects for therapeutic targeting. Trends Immunol 2011, 32:358-363.
46. Valenzuela J.O., Iclozan C., Hossain M.S., et al. PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. J Clin Invest 2009, 119:3774-3786.
47. O'Connell R.M., Rao D.S., Chaudhuri A.A., Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010, 10:111-122.
48. Ranganathan P., Heaphy C.E., Costinean S., et al. Regulation of acute graft-versus-host disease by microRNA-155. Blood 2012, 119:4786-4797.
49. Ma H., Lu C., Ziegler J., et al. Absence of Stat1 in donor CD4+ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. J Clin Invest 2011, 121:2554-2569.
50. Laurence A., Amarnath S., Mariotti J., et al. STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease. Immunity 2012, 37:209-222.
51. Cetkovic-Cvrlje M., Uckun F.M. Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model. Br J Haematol 2004, 126:821-827.